Diversified Portfolios Inc. Has $317,000 Stake in Bristol-Myers Squibb (NYSE:BMY)
Diversified Portfolios Inc. Has $317,000 Stake in Bristol-Myers Squibb (NYSE:BMY)
Diversified Portfolios Inc. trimmed its stake in Bristol-Myers Squibb (NYSE:BMY – Get Rating) by 46.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 4,405 shares of the biopharmaceutical company's stock after selling 3,786 shares during the period. Diversified Portfolios Inc.'s holdings in Bristol-Myers Squibb were worth $317,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
多元化的投資組合公司在第四季度削減了其在百時美施貴寶（紐約證交所代碼：BMY-獲得評級）的股份 46.2％，Holdingschannel.com 報告。該公司在此期間出售 3,786 股後，擁有該生物製藥公司股票的 4,405 股。多元化投資組合公司 '從最近向美證券交易委員會（SEC）提交的文件中，百時美施貴寶的持股價值為 317,000 美元。
Several other hedge funds and other institutional investors also recently bought and sold shares of BMY. New Millennium Group LLC acquired a new stake in Bristol-Myers Squibb in the 2nd quarter worth $31,000. My Personal CFO LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter worth $35,000. Clear Investment Research LLC bought a new position in shares of Bristol-Myers Squibb during the 3rd quarter worth about $36,000. Western Pacific Wealth Management LP boosted its position in shares of Bristol-Myers Squibb by 878.6% during the 3rd quarter. Western Pacific Wealth Management LP now owns 548 shares of the biopharmaceutical company's stock valued at $38,000 after acquiring an additional 492 shares in the last quarter. Finally, Mitsubishi UFJ Morgan Stanley Securities Co. Ltd. acquired a new stake in shares of Bristol-Myers Squibb during the 4th quarter valued at about $40,000. 75.51% of the stock is currently owned by institutional investors and hedge funds.
其他幾個對沖基金和其他機構投資者最近還買賣了 BMY 的股票。新千禧集團有限責任公司在第二季度收購了百時美施貴寶的新股份，價值 31,000 美元。我的個人首席財務官有限責任公司在第四季度收購了百時美施貴寶的新股份，價值 35,000 美元。明確投資研究有限責任公司在第三季度期間買了百時美施貴寶股份的新位置，價值約 36,000 美元。西太平洋財富管理有限公司在第三季度提高了其在百時美施貴寶股份的地位 878.6%。西太平洋財富管理有限公司在上一季度額外收購 492 股後，擁有該生物製藥公司股票的 548 股價值 38,000 美元。最後，三菱日聯摩根士丹利證券有限公司Ltd. 在第四季度收購了百時美施貴寶股份的新股份，價值約為 40,000 美元。75.51％ 的股票目前由機構投資者和對沖基金擁有。
Insider Activity
內幕活動
In other news, CEO Giovanni Caforio sold 240,000 shares of the business's stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $74.65, for a total value of $17,916,000.00. Following the completion of the transaction, the chief executive officer now directly owns 236,104 shares in the company, valued at approximately $17,625,163.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In related news, CEO Giovanni Caforio sold 240,000 shares of the company's stock in a transaction that occurred on Monday, February 6th. The shares were sold at an average price of $74.65, for a total transaction of $17,916,000.00. Following the completion of the transaction, the chief executive officer now directly owns 236,104 shares in the company, valued at approximately $17,625,163.60. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Ann Powell sold 11,183 shares of the company's stock in a transaction that occurred on Monday, February 6th. The stock was sold at an average price of $74.69, for a total transaction of $835,258.27. Following the transaction, the executive vice president now owns 23,043 shares of the company's stock, valued at $1,721,081.67. The disclosure for this sale can be found here. Corporate insiders own 0.09% of the company's stock.
在其他消息中，首席執行官喬瓦尼·卡福里奧在 2 月 6 日週一發生的交易中出售了 240,000 股該企業的股票。這些股票以平均價格 74.65 美元出售，總價值為 17,916 萬美元。交易完成後，首席執行官現直接擁有該公司 236,104 股股份，價值約為 17,625,163.60 美元。出售已在與證券交易委員會提交的文件中披露，該文件可通過以下方式獲得 這個鏈接。在相關新聞中，首席執行官喬瓦尼·卡福里奧在 2 月 6 日（週一）發生的交易中出售了 240,000 股該公司股票的股票。這些股票以 74.65 美元的平均價格出售，總交易額為 17,916 萬美元。交易完成後，首席執行官現直接擁有該公司 236,104 股股份，價值約為 17,625,163.60 美元。該交易在與 SEC 提交的文件中披露，該文件可通過以下方式獲得 證券交易所網站。此外，執行副總裁安·鮑威爾在 2 月 6 日（星期一）發生的交易中出售了該公司股票的 11,183 股。該股票以 74.69 美元的平均價格出售，總交易額為 835,258.27 美元。交易完成後，執行副總裁現擁有該公司股票的 23,043 股，價值為 1,721,081.67 美元。可以找到此次銷售的披露 這裡。企業內部人士擁有公司股票的 0.09%。
Bristol-Myers Squibb Stock Performance
百時美施貴寶股票表現
Bristol-Myers Squibb stock traded up $1.11 during midday trading on Friday, hitting $69.31. The company's stock had a trading volume of 8,953,242 shares, compared to its average volume of 8,381,778. Bristol-Myers Squibb has a 1-year low of $65.28 and a 1-year high of $81.43. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.25 and a quick ratio of 1.14. The company has a 50-day moving average price of $70.06 and a two-hundred day moving average price of $72.79. The company has a market cap of $145.78 billion, a price-to-earnings ratio of 23.49, a PEG ratio of 1.48 and a beta of 0.46.
百時美施貴寶股票周五中午交易期間上漲 1.11 美元，觸及 69.31 美元。該公司的股票交易量為 8,953,242 股，而其平均交易量為 8,381,778 股。百時美施貴寶擁有 1 年低點 65.28 美元和 1 年高點 81.43 美元。該公司的債務與權益比率為 1.13，流動比率為 1.25，快速比率為 1.14。該公司擁有 50 天的移動平均價格為 70.06 美元，兩百天移動平均價為 72.79 美元。該公司的市值為 1457.8 億美元，股價與收益比率為 23.49，掛鉤比率為 1.48，測試版為 0.46。
Bristol-Myers Squibb (NYSE:BMY – Get Rating) last issued its earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.82 EPS for the quarter, beating the consensus estimate of $1.71 by $0.11. The company had revenue of $11.41 billion during the quarter, compared to analysts' expectations of $11.20 billion. Bristol-Myers Squibb had a net margin of 13.71% and a return on equity of 51.60%. The business's revenue for the quarter was down 4.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.83 EPS. As a group, sell-side analysts predict that Bristol-Myers Squibb will post 8.06 earnings per share for the current year.
百時美施貴寶 (紐約證交所代碼:BMY — 獲得評級) 上次公佈其盈利業績，日期為 2 月 2 日（星期四）。這家生物製藥公司報告了本季度每股 1.82 美元的每股收益，超過了 1.71 美元的共識估計。該公司在本季度的營收為 1141 億美元，而分析師的預期為 11.20 億美元。百時美施貴寶的淨利潤率為 13.71%，股本回報率為 51.60%。該季度的業務收入較去年同期下降了 4.8%。在上一年同期，該公司的每股收益為 1.83 美元。作為一個集團，賣方分析師預測，百時美施貴寶將公佈本年度每股 8.06 盈利。
Bristol-Myers Squibb Announces Dividend
百時美施貴寶宣佈股息
The company also recently announced a quarterly dividend, which will be paid on Monday, May 1st. Stockholders of record on Monday, April 10th will be given a $0.57 dividend. This represents a $2.28 annualized dividend and a dividend yield of 3.29%. The ex-dividend date of this dividend is Thursday, April 6th. Bristol-Myers Squibb's payout ratio is presently 77.29%.
該公司最近還宣布了季度股息，將於 5 月 1 日（週一）支付。4 月 10 日（星期一）記錄股東將獲得 0.57 美元的股息。這代表 2.28 美元的年度股息和 3.29％ 的股息收益率。該股息的除息日期為 4 月 6 日（星期四）。百時美施貴寶的派彩比率目前為 77.29%。
Analyst Ratings Changes
分析師等級變更
Several analysts have recently weighed in on BMY shares. Atlantic Securities lifted their target price on shares of Bristol-Myers Squibb from $88.00 to $90.00 and gave the company an "overweight" rating in a research report on Friday, February 3rd. Cantor Fitzgerald started coverage on shares of Bristol-Myers Squibb in a research report on Tuesday, January 17th. They set an "overweight" rating and a $95.00 target price on the stock. StockNews.com started coverage on shares of Bristol-Myers Squibb in a research report on Thursday, March 16th. They set a "strong-buy" rating on the stock. Morgan Stanley boosted their price target on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "underweight" rating in a research report on Friday, February 3rd. Finally, Jefferies Financial Group initiated coverage on shares of Bristol-Myers Squibb in a research report on Monday, March 6th. They issued a "hold" rating and a $62.00 price target on the stock. One analyst has rated the stock with a sell rating, seven have given a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $79.69.
幾位分析師最近對 BMY 股票進行了權衡。大西洋證券將百時美施貴寶股票的目標價格從 88.00 美元提高至 90.00 美元，並在 2 月 3 日（星期五）的一份研究報告中給予該公司「超重」評級。坎托·菲茨杰拉德開始覆蓋百時邁施貴寶的股份在週二的研究報告, 1 月 17 日.他們設定了「超重」評級和 95.00 美元的股票目標價格。Stocknews.com 於 3 月 16 日（星期四）在一份研究報告中開始報導百時美施貴寶的股份。他們在股票上設置了「強買」評級。摩根士丹利將百時美施貴寶股票的價格目標從 60.00 美元提高至 62.00 美元，並在 2 月 3 日（星期五）的一份研究報告中給予該公司「體重過輕」評級。最後，富瑞金融集團於 3 月 6 日（星期一）在一份研究報告中啟動對百時美施貴寶股份的報導。他們發布了「持有」評級和 62.00 美元的股票價格目標。一位分析師對該股票進行了賣出評級，七人給出了持有評級，七人給出了買入評級，另一位分析師對該公司發出了強大的買入評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為「中等買入」，平均目標價為 79.69 美元。
About Bristol-Myers Squibb
關於百時美施貴寶
(Get Rating)
(取得評分)
Bristol Myers Squibb Co engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It offers chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
布里斯托爾邁爾斯 Squibb 公司從事生物製藥產品的發現，開發，許可，製造，營銷，分銷和銷售。它提供化學合成的藥物或小分子和產品從稱為生物製劑的生物過程產生.該公司成立於 1933 年 8 月，總部位於紐約州紐約。
Further Reading
進一步閱讀
- Get a free copy of the StockNews.com research report on Bristol-Myers Squibb (BMY)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
- 獲取有關百時美施貴寶（BMY）的股票新聞網研究報告
- 市場節拍週的回顧 — 3 月 27 日 — 3/31
- 什麼是黃金 IRA 退休賬戶，它是一項可行的投資嗎？
- 是 Braze 公司準備火箭更高嗎？
- 穆倫汽車製造交貨；短擠壓成為可能
- 前線可以保持這種勢頭嗎？
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY – Get Rating).
想看看還有哪些對沖基金持有 BMY？ 訪問 Holdingschannel.com 以獲取百時美施貴寶（紐約證交所代碼：BMY — 獲得評分）的最新 13 樓文件和內幕交易。
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
接收百時美施貴寶日報的最新消息和評分 -在下面輸入您的電子郵件地址，以通過 MarketBeat.com 的免費每日電子郵件通訊接收百時美施貴寶及相關公司的最新新聞和分析師評級的簡要每日摘要。
譯文內容由第三人軟體翻譯。